The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Mark Kelley, Melissa Fishel receive $2.4M NCI grant to develop pancreatic cancer treatments

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Mark Kelley

Melissa Fishel

Mark Kelley and Melissa Fishel, two researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, received a five-year, $2.4 million grant from NCI to explore therapies that target the critical pathways pancreatic tumors use to survive.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions”

How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
By Paul Goldberg and Claire Marie Porter
Clinical Roundup

TAMP procedure shows 52% reduction in pancreatic tumor metabolic activity, Moffitt case study shows

Researchers at Moffitt Cancer Center have published a case study highlighting the potential optimization of the TAMP, or trans-arterial micro-perfusion, procedure with RenovoCath to deliver intra-arterial gemcitabine (a commonly used chemotherapy) directly near a tumor (rather than traditional systemic IV administration) in a patient with locally advanced pancreatic cancer. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account